Mather Group LLC. increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 21.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,591 shares of the medical research company’s stock after buying an additional 1,889 shares during the quarter. Mather Group LLC.’s holdings in Amgen were worth $4,464,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in shares of Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after acquiring an additional 2,261,544 shares during the last quarter. State Street Corp increased its holdings in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Amgen by 12.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after purchasing an additional 605,928 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Amgen in the 2nd quarter valued at approximately $1,831,903,000. Finally, Invesco Ltd. raised its position in shares of Amgen by 7.2% in the 4th quarter. Invesco Ltd. now owns 4,788,460 shares of the medical research company’s stock valued at $1,567,311,000 after purchasing an additional 321,173 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Amgen
In other news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 6,222 shares of company stock valued at $2,540,926. Company insiders own 0.85% of the company’s stock.
Amgen Trading Up 1.9%
Shares of NASDAQ:AMGN opened at $434.03 on Friday. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $447.03. The stock has a market cap of $234.65 billion, a price-to-earnings ratio of 26.98, a PEG ratio of 3.12 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The business has a 50-day moving average price of $415.11 and a 200-day moving average price of $374.35.
Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.94 EPS for the current year.
Amgen Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.
Analysts Set New Price Targets
A number of analysts recently commented on AMGN shares. Oppenheimer reiterated an “outperform” rating on shares of Amgen in a research note on Wednesday, September 23rd. Citigroup upped their price target on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Robert W. Baird raised their price target on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. HSBC downgraded shares of Amgen from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $445.00 to $425.00 in a research note on Thursday, September 10th. Finally, Scotiabank lifted their price objective on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $387.93.
Get Our Latest Stock Report on AMGN
Amgen News Roundup
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, potentially expanding the drug’s addressable market in a condition with limited treatment options. What Could Amgen 70% Remission Trial Result Mean For Its Pipeline?
- Positive Sentiment: UBS raised its price target for AMGN to $470, signaling greater confidence in the company’s outlook and supporting investor sentiment. UBS raises target for Amgen stock to USD 470.00
- Positive Sentiment: Investors are focusing on Amgen’s broader pipeline, including the MariTide obesity program, planned Phase 3 diabetes studies and recent regulatory momentum. These programs offer potential long-term growth beyond Amgen’s established products. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
- Positive Sentiment: Erste Group Bank increased its FY2027 EPS forecast to $24.66 from $24.36, adding to evidence that some analysts see improving earnings potential.
- Positive Sentiment: A broader rotation away from technology stocks toward defensive and consumer-oriented companies may be helping support sentiment toward large pharmaceutical stocks.
- Neutral Sentiment: Amgen’s dividend yield is approximately 2.3%. Its dividend-growth prospects are being compared favorably with Merck’s because of Amgen’s reported cash-flow cushion, although the analysis does not represent a new dividend announcement. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
- Negative Sentiment: Risks remain: Bank of America Securities maintained a Sell rating, while recent insider activity showed seven sales and no purchases over six months. Some previously published analyst targets also remain well below the current trading range, highlighting valuation concerns. Bank of America Securities Remains a Sell on Amgen
Amgen Company Profile
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.
Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.
Read More
- Five stocks we like better than Amgen
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
